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Immunofluorescence chemistry and confocal microscopy-For cell viability assays, cells were re-plated into 6-well plates after transfection. After 12 h, cells were treated with 1 nM R1881 or ethanol for additional 36 h. Cells were examined under a Zeiss LSM-510 confocal laser microscope (Carl Zeiss, Inc., Germany). Cells were photographed with a wavelength of 488 nm for GFP. For immunofluorescence chemistry, cells on coverslips (Eppendorf Scientific, Inc., Hamburg, Germany) were washed briefly in 1xPBS and fixed for 20 min in 2% paraformaldehyde (Toussins) in 1 x PBS. Cells were permeabilized by incubating with 0.3% Triton X-100 for 15 min. Cells were washed three times in 1xPBS, and incubated in blocking buffer (5% goat serum in 1xPBS) for 1 h at room temperature. Cells were incubated with a rabbit anti-AR polyclonal antibody (1:500) and a mouse anti-FLAG monoclonal antibody (1:1000) for 2 h at room temperature. After washing with 1xPBS three times for 5 min each, cells were incubated for 1 h at room temperature with the following secondary antibodies: Alexa Fluor 594 goat anti-rabbit IgG conjugate (Molecular Probes, Inc.) (1:1000), and Alexa Fluor 488 goat antimouse IgG conjugate (Molecular Probes, Inc.) (1:1000) prepared in blocking buffer for one hour at room temperature. Coverslips were washed with three changes of 1xPBS for 5 min each and mounted in ProLong (Molecular Probes, Inc.). Cells were analyzed with a laser-scanning microscope LSM510. Argon Ion and HeNe lasers were used to excite FITC and Texas red fluorescence, respectively, and UV laser was used to excite DAPI.
Cell death assay-Nuclear fragment and chromatin condensation were measured as described previously (40, 43) . Briefly, cells treated for 48h after transfections were collected at 4ºC.
Supernatant media was aspirated, and cells were treated with fixative solution (4% formaldehyde in 1xPBS). Bis-benzimide was added at a final concentration of 1 µg/ml and incubated for 10 min at room temperature. Cell aliquots were placed on slides and viewed under UV and a wavelength of 488 nm (Carl Zeiss Axiophot). Green cells with signs of chromatin condensation and/or nuclear fragmentation (apoptotic) were scored as dead.
Purification of FLAG-tagged FKHR proteins-LNCaP cells grown in fifty 150-mm dishes
were transfected with FLAG-tagged FKHR by electroporation. All subsequent steps were performed at 4 o C. Cells were washed once with ice-cold 1xPBS and lysed in Triton lysis buffer (50 mM Tris HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100) plus 1% of protease inhibitor cocktail (Sigma). Cells were lysated at 4 o C for 30 min. Whole cell lysates were cleared at 12,000 x g for 20 min. Protein samples were incubated with anti-FLAG M2 affinity resins (Sigma) in protein binding buffer (190 mM NaCl, 50 mM Tris-HCl, pH 7.4, 6 mM EDTA, 2.5%
Triton X-100) for 2 h. The beads were washed three times with washing buffer (150 mM NaCl, 10 mM Tris-HCl, pH 9.0, 5 mM EDTA, 0.1% Triton X-100) and once with Tris-buffered saline (10 mM Tris-HCl, pH 7.4, 150 mM NaCl). Proteins were eluted with SDS-PAGE sample buffer (Invitrogen), analyzed by SDS-PAGE, and stained with GelCode blue (Pierce) and Western blotting using anti-FKHR antibody (Cell Signaling). Peptides were extracted from the gel bands, first with 2% formic acid followed by 70%
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acetonitrile / 30% water / 0.1% formic acid. (Fig. 1B, right panel) . There was only a slight decease in cell viability when cells were transfected with wild-type FKHR, FKHR(WT) (Fig. 1C, left panel) . This confirms a previous report that wild-type FKHR is only partially active because of its phosphorylation state (23) . This slight difference was attenuated following androgen treatment (Fig. 1C, right panel) .
Mass spectrometry-LC-MS/MS
Co-transfection of FKHR(WT) along with PTEN resulted in a marked decrease in cell viability (Fig. 1D , left panel), which is consistent with the decreased phosphorylation of FKHR and thereby activation of FKHR in cells in the presence of PTEN (23) . This effect of PTEN was inhibited by androgen treatment (Fig. 1D , right panel). As shown in Fig. 1E , PTEN-induced loss of cell viability was also inhibited markedly by androgens.
Next we measured apoptosis by a nuclear condensation and fragmentation assay (40) . The constitutively active FKHR induced more than 15% apoptosis in LNCaP cells, and this was largely inhibited by androgens (Fig. 2) . The death of LNCaP cells induced by FKHR(WT) alone or plus PTEN was markedly abrogated by androgen treatment. Androgens also inhibited PTENinduced cell death (Fig. 2) . Importantly, the androgen-mediated effects were reversed completely by co-treatment of cells with an androgen antagonist, bicalutamide, indicating that this is an androgen receptor-dependent event. Therefore, androgens inhibit cell death that is either induced by activated FKHR or potentiated by PTEN. Moreover, the androgen receptor appears to mediate these effects. However, this effect of PTEN was diminished by androgen treatment ( (Fig. 3C ). In contrast, androgen treatment markedly inhibited transcription from the 3xIRS reporter (Fig. 3C) . A similar inhibitory effect of androgens on FKHR transactivation was observed with a luciferase vector, which contains an FKHR-response element from the promoter of the FasL gene (Fig. 3D) . Thus, these results suggest that the inhibitory effects of androgens occur at the level of FKHR.
The effect of androgens on nuclear localization of the FKHR protein-Nuclear localization is required for the normal function of forkhead transcription factors (23, 26, 34) . Active FKHR is retained in the nucleus, whereas, inactive FKHR remains in the cytoplasm. Thus, we were interested in determining whether androgens inhibit transcriptional activity of the FKHR protein by blocking its nuclear localization. Since expression levels of endogenous FKHR are quite low, we utilized transfected FKHR. As shown in The androgenic effect was further examined in BPH-1, an immortalized prostatic cell line which does not express endogenous androgen receptor (43) . The similar dynamic changes in FKHR proteins were induced by ectopic expression of the androgen receptor in BPH-1 cells (Fig. 5E ).
Taken together, these data indicate that androgens affect expression of FKHR protein through the androgen receptor.
Time course studies showed that the effect of androgens on FKHR protein was detected at 48h or later following androgen administration ( Fig. 5C ), suggesting that this is not a direct transcriptional response. Also, the 60-kDa form of the FKHR protein was inhibited by treatment of cells with cycloheximide, an inhibitor of new protein synthesis (Fig. 5D) . Thus, the effect of androgens on FKHR protein appears to require new protein synthesis. This supports the conclusion that androgens are inducing the expression of a protein(s), which in turn affects changes in FKHR.
In order to determine whether androgen-induced appearance of the 60 kDa species of FKHR originates from alternative splicing of pre-exist exons, we performed RT-PCR for the mRNA isolated from LNCaP cells treated with androgens. The human FKHR gene contains three exons (46) . Therefore, forward and reverse primers were designed from sequences adjacent to the 5' and 3' ends of the exon 2 ( Fig. 6A , top). Only one PCR product was observed (the expected 1.5 kb band), and no additional bands were amplified from the LNCaP cells treated with androgens ( Fig. 6A , bottom). When reverse transcriptase was omitted from the reaction mixture, no amplification was observed, suggesting that the observed PCR product was amplified from the synthesized cDNA. Also, no extra mRNA species was detected by Northern blot analysis by using the entire ORF sequence as a probe (Fig. 6B ), suggesting that unpredictable gene arrangement is not involved. Therefore, these results suggest that the effect of androgens on FKHR may occur through a post-translational mechanism that likely affects the FKHR protein itself.
The effect of protease inhibitors on FKHR protein-We sought to determine whether proteases play a role in the androgen-mediated effects on the FKHR proteins. LNCaP cells were treated with a panel of protease inhibitors. After treatment with R1881, LNCaP cells were exposed to MG132, a broad-spectrum inhibitor of proteasomes. In the absence of MG132, androgens induced an accumulation of the endogenous 60-kDa FKHR (Fig. 7A) . However, the process was inhibited by the exposure of cells to MG132 (Fig. 7A) . Similar results were obtained in studies with the transfected FLAG-tagged FKHR protein (Fig. 7B, left panel) . Since MG132 is not specific for proteasomes (47, 48) , we treated LNCaP cells with a highly specific proteasome inhibitor lactacystin (49) . No inhibitory effect of lactacystin was observed (Fig. 7B , right panel),
suggesting that proteasomes are not involved in formation of the 60-kDa FKHR. These findings are similar to the protease-mediated cleavage of β-secretase that is sensitive to MG132, but resistance to lactacystin (50) . Thus, a mechanism other than proteasome degradation appears to underlie the proteolysis of the FKHR protein.
Next we treated LNCaP cells with the lysosomal acidic cysteine protease inhibitors chloroquine, ammonium chloride, and leupeptin (48, 51, 52) . Treatment of LNCaP cells with chloroquine inhibited accumulation of endogenous 60-kDa FKHR induced by androgens (Fig. 7C ).
Chloroquine also inhibited androgen-induced formation of the 60-kDa FLAG-tagged FKHR in a dose-dependent manner ( kDa product is a natural cleavage site of FKHR because K515 was also detected by MS in a peptide in the full-length protein ( Fig. 8B and 8C) . Indeed, the mass spectrometry results of the intact and breakdown proteins suggest that the protease cleavage site of FKHR exists between K515 and T560.
Because the candidate protease might be an acidic cysteine protease, we were interested to determine whether mutations in the basic amino acids in the potential cleavage region (see top panel of Fig. 9 A) would generate cleavage resistance. As shown in Fig. 9A , conversion of Arg 537 to a Gly in FKHR largely abolished androgen-induced accumulation of the 60 kDa product.
However, no effect of mutations at the basic amino acid residues R554 or K559 was obtained on protease cleavage of the FKHR protein. Importantly, mutating the amino acid adjacent to R537 (P538G) had no effect on androgen-induced FKHR cleavage. These results support the specificity of the R537G mutation in resistance to FKHR cleavage. Therefore, given the basic nature of R537, the mutagenesis data suggest that this amino acid might be a cleavage site of the androgen-regulated acidic cysteine protease. It is worth mentioning that despite the R537G mutation, a trace degree of cleavage was still observed (Fig. 9A) , suggesting either incomplete resistance to proteolysis due to a single-point mutation or the presence of minor cleavage sites near R537.
To assess the effect of the R537G mutation on the biological function of FKHR, we compared Fig. 9B ) and cell death (Fig. 9C) . However, the androgenic effects on transcriptional activity and apoptosis were abrogated by the R537G mutation in FKHR (Fig. 9B,   9C ). Therefore, the R537G mutation not only establishes resistance of FKHR to androgeninduced protease cleavage, but also diminishes the inhibitory effect of androgens on its biological function. Interestingly, the transcriptional activity of the FKHR(AAA)-R537G was slightly lower than FKHR(AAA) (Fig. 9B) , the reason for which is unclear.
Cellular localization and transcriptional activity of the C-terminal truncated FKHR
proteins-As suggested by results of mass spectrometry (Fig. 8) and mutagenesis ( Fig. 9 ), R537 appears to be a potential cleavage site of FKHR induced by androgens. In an attempt to gain insight into the function of the breakdown product of FKHR, we generated two mutants, WT(∆) and AAA(∆), in which amino acids from the C-terminal end (after the residue R537) were truncated in FKHR(WT) and FKHR(AAA), respectively. We examined the cellular localization of these truncated FKHR proteins in LNCaP cells. As shown in Fig. 10A , transfected WT(∆) was localized in the cytoplasm in the absence of PTEN, but was localized in the nucleus following PTEN transfection (Fig. 10B) . In contrast, AAA(∆) was localized in the nucleus in the absence of PTEN (Fig. 10C ). This is similar to the cellular localization of FKHR(AAA) (23) . The cellular localization of these mutants was not affect by androgen treatment (Fig. 10D-F) . These results suggest that lack of the C-terminal fragment (AA 538-655 ) does not affect nuclear localization of the protein.
To test whether truncation of the C-terminal end at R537 would affect the transcriptional activity of FKHR, we measured the reporter gene activity in LNCaP cells tranfected with AAA(∆). Little or no activity was obtained in cells transfected with AAA(∆) (Fig. 11A) , suggesting that lack of the C-terminal end after R537 leads to loss of transcriptional activity of FKHR. Restoration of PTEN into LNCaP cells induced transactivation of endogenous FKHR (Fig. 11B) . This activity was diminished by ectopic expression of WT(∆) in a dose-dependent manner (Fig. 11B ). Ectopic expression of the truncated protein, AAA(∆), had a similar inhibitory effect on transfected fulllength FKHR(AAA) (Fig. 11 C) . As a control, transfection of the constitutively active FKHR(AAA) resulted in a dramatic increase in transcription of the reporter gene ( Fig. 11A and   11C ). Therefore, these data suggest that lack of the C-terminal domain results in loss of transcriptional activity of truncated protein, but gain of an inhibitory activity of the intact FKHR protein.
Discussion
Androgens have been linked to a number of survival pathways. For example, they protect prostate cancer cells from death induced by etoposide (58 A previous study has demonstrated that synthetic oligonucleotides of the androgen response element (ARE) induce apoptosis in LNCaP cells (62) . This suggests that ARE-dependent transcription may play an essential role in prostate cancer cell survival. The protective effect of androgens on wortmannin-induced death of LNCaP cells appears to be mediated by a similar mechanism. However, it appears to be indirect, since no androgenic effect was detected when dihydrotestosterone was added simultaneously or after wortmannin was applied to cells (61) .
Likewise, in our current study, neither the inhibitory effect of androgens on FKHR-induced cell death nor the androgen-induced proteolysis of FKHR protein was detected until 48 h of androgen treatment. Moreover, the androgenic effect was abolished by blockage of new protein synthesis.
Therefore, it appears that the inhibitory effect of androgens on FKHR-induced apoptotic death of LNCaP cells is mediated primarily through an indirect mechanism.
FKHR is a nuclear transcription factor (29, 38) . The DNA binding domain of the human FKHR is located between amino acid residues 158 and 258, and transactivation domain is at the Cterminal end (AA 596-655 ) (63) . The current study demonstrates that the breakdown product of 
